178 related articles for article (PubMed ID: 7111181)
1. [Biological availability of two theophylline preparations (author's transl)].
Kaik G
Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
[No Abstract] [Full Text] [Related]
2. [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)].
Wemhöner S; Oellerich M; Sybrecht G
Prax Klin Pneumol; 1981 Jan; 35(1):36-41. PubMed ID: 7208408
[No Abstract] [Full Text] [Related]
3. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
Wiessmann KJ
Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
[TBL] [Abstract][Full Text] [Related]
4. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
Ranke C; Schmidt G; Oellerich M; Sybrecht GW
Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
[No Abstract] [Full Text] [Related]
5. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
Harkaway PS; Conlon PF; Hirsh JD; Allen WT
J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
[TBL] [Abstract][Full Text] [Related]
6. [Theophylline therapy in obstructive respiratory diseases. 2. Theophyllin-retard preparations for the long-term treatment of non-smokers with or without cardiac insufficiency (author's transl)].
Wemhöner S; Oellerich M; Sybrecht G
Prax Klin Pneumol; 1981 Jan; 35(1):42-6. PubMed ID: 6782562
[No Abstract] [Full Text] [Related]
7. [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
Wiesner B; Sehrt I; Iwainsky H
Z Erkr Atmungsorgane; 1984; 162(1):3-10. PubMed ID: 6719957
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of bioavailability and pharmacokinetic profiles between Theodur and a new sustained-release theophylline formulation].
Morishita M; Nagai T; Ishizaki T; Suganuma T; Kushida K; Minegishi A
Arerugi; 1986 Nov; 35(11):1099-104. PubMed ID: 3827603
[No Abstract] [Full Text] [Related]
9. [Bioavailability of oral theophylline preparations (author's transl)].
Plavsić F; Vrhovac B; Bakran I
Lijec Vjesn; 1978 Oct; 100(10):610-2. PubMed ID: 745496
[No Abstract] [Full Text] [Related]
10. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
[TBL] [Abstract][Full Text] [Related]
11. Theophylline-mexiletine interaction: a case report.
Kendall JD; Chrymko MM; Cooper BE
Pharmacotherapy; 1992; 12(5):416-8. PubMed ID: 1437703
[TBL] [Abstract][Full Text] [Related]
12. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
Harder S; Staib AH; Stauder J
Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
[No Abstract] [Full Text] [Related]
13. Slow-release theophylline for the management of chronic asthma.
Hendeles L; Weinberger M
Singapore Med J; 1985 Feb; 26(1):83-90. PubMed ID: 3895446
[No Abstract] [Full Text] [Related]
14. Clinical results obtained from a new controlled release theophylline preparation.
Nolte D
Br J Clin Pract Suppl; 1984; 32():14-7. PubMed ID: 6432017
[No Abstract] [Full Text] [Related]
15. [Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases].
Nolte D; Dusik B
Fortschr Med; 1983 Jul; 101(25):1203-6. PubMed ID: 6884955
[TBL] [Abstract][Full Text] [Related]
16. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
Pollert I
Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
[No Abstract] [Full Text] [Related]
17. [Comparative bioavailability of 2 oral theophylline sustained-release preparations].
Tritthart W; Lücker PW; Fáy E; Buchebner J
Arzneimittelforschung; 1983; 33(11):1603-6. PubMed ID: 6686457
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of obstructive respiratory tract diseases. Study of afonilum retard in 3,512 patients].
Eichhorn J; Perré R
Med Welt; 1982 Dec; 33(50):1834-7. PubMed ID: 6762480
[No Abstract] [Full Text] [Related]
19. Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT.
Birkett DJ; Coulthard KP; Lines D; Grgurinovich N
Br J Clin Pract Suppl; 1984; 35():17-23. PubMed ID: 6433954
[No Abstract] [Full Text] [Related]
20. [Serum levels and urinary and fecal excretion of ethamicylin HCI (solucylin). Oral and intravenous administration (author's transl)].
Torres A; Rovira J; Zapatero D; Vilageliu J; Ribalta M; Bruseghini L
Arch Farmacol Toxicol; 1980 Dec; 6(3):237-46. PubMed ID: 7305455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
